A list of puns related to "Radiopharmaceuticals"
Introduced: Sponsor: Sen. Marsha Blackburn [R-TN]
This bill was referred to the Senate Committee on Finance which will consider it before sending it to the Senate floor for consideration.
Austin, TX; August 25, 2021 – QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.
“This IND clearance is another major milestone for QSAM and the advancement of CycloSam. We expect to commence our Phase 1 open-label dose escalation trial in bone cancer patients by the end of this year. These trials will be intended to investigate the efficacy, safety, tolerability and pharmacokinectics of CycloSam to establish the optimal dose for pivotal Phase 2/3 clinical trials,” stated the Company’s Co-Founder and CEO, Douglas R. Baum. “The clearance of our IND also continues to validate our data-driven approach in oncology drug development and sets the stage for additional aggressive efforts we are undertaking in pediatric and adult cancer therapies.”
CycloSam is expected to be a significantly improved formulation of a previously FDA-approved radiopharmaceutical. This novel drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.
About QSAM Biosciences: QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed a previous FDA-approved and commercially available radiopharmaceutical product indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits. CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium-154 impurity) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over makin
... keep reading on reddit ➡Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions, announced today favorable results from a study to evaluate the radioactive impurity levels in its flagship drug candidate Samarium-153-DOTMP (aka CycloSam®). The results of this study are positive indicators about the safety profile and potential expanded uses of CycloSam if ultimately approved for commercial usage by the U.S. Food and Drug Administration (FDA).
The study, conducted by leading radiopharmaceutical research firm, IsoTherapeutics Group, LLC, confirmed that the long-lived radionuclidic impurities of Europium-154 (Eu-154) in CycloSam are decreased over 40-fold to nearly non-detectable levels from those reported for a similar radiopharmaceutical product previously approved by the FDA for commercial usage. The findings also indicate significantly less buildup of these impurities, which enhances the clinical utility of CycloSam, potentially allowing safe, multiple dosing regimens, and possibly leading to broader therapeutic applications across multiple indications.
“We are very pleased with the results of this study as it confirms CycloSam’s superior safety profile for impurities and the integrity of our manufacturing procedures. Developing a radiopharmaceutical for the treatment of multiple types of primary and metastatic bone cancers that safely enables higher and multiple dosing significantly widens the therapeutic applications and utility of our product,” stated Douglas R. Baum, CEO and Co-Founder of QSAM.
QSAM expects to enter Phase 1 clinical trials for CycloSam in the first half of this year. The company, through its exclusive, worldwide license agreement with IsoTherapeutics Group, has issued patents that encompasses Sm-153 and reduced Euro
... keep reading on reddit ➡As more and more (traditional?) nuclear reactors are being shut down around the world, will the nuclear medicine field be negativy affected? Or is there a trend where nuclear reactors are repurposed for research purposes (including medical research), which may positively affect the field?
Hi everyone!
I’m looking to go into a masters in organic chemistry researching radiopharmaceuticals. I was wondering if anybody had any ideas for possible research topics, or what hot topics there currently are in radiopharmaceuticals (maybe focusing on their synthesis?).
Any help would be much appreciated, thank you!
I’m trying to get a copy of an obscure article that I absolutely need for my thesis, but my university and it’s network of affiliated libraries don’t subscribe to the journal it’s in. The authors also haven’t answered my emails... do any of you have access/could share a PDF of it?
Thanks so much in advance to anyone that can help me out!
As more and more (traditional?) nuclear reactors are being shut down around the world, will the nuclear medicine field be negativy affected? Or is there a trend where nuclear reactors are repurposed for research purposes (including medical research), which may positively affect the field?
Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.